The distinctive biomarkers in lung cancer are mutations in the epidermal growth factor receptor (EGFR) [9] or gain-of-function translocations and inversions involving the anaplastic lymphoma receptor tyrosine kinase (ALK) [10]. This evidence concerns the gene EGFR and lung cancer.